Toggle light / dark theme

Each time our cells divide, the protective caps that keep our chromosomes from fraying, called telomeres, lose a bit of their DNA. Telomeres shorten steadily as we age, but in certain medical conditions like dyskeratosis congenita, the process is accelerated.

“Your telomeres determine your lifeline; how long they are determines how old your body is,” says Becca Hudson, who was diagnosed with at age 14. “My was below the first percentile for my age.”

Trying out for cheerleading, 14-year-old Becca was pulled when testing found something amiss with her blood work. She had very low counts of platelets, red cells, and white cells. Her doctor called later that day and said she should be admitted that night to Boston Children’s Hospital.

A bit long 😪

Anyone can have a Mastodon server. People turned their backs on Tom, whose Myspace was the best space. Zuckerberg copied both Tom and the Twins. I rejoined Myspace after Facebook started harrassing my account because of the Virality Project because I questioned the popular vaccines, and told people how long it took to create an effective vaccine, and the effectiveness of the BCG vaccine I took as an infant. They silenced me.

In this group even before Musk paid for Twitter I posted about Mastodon, an open source Twitter option, and I still will pay for a blue tick. I won’t pay for anything Zuckerberg does what Mastodon already did, and people line up like sheep, yet… More.


Mastodon: @[email protected]

Discovering new materials and drugs typically involves a manual, trial-and-error process that can take decades and cost millions of dollars. To streamline this process, scientists often use machine learning to predict molecular properties and narrow down the molecules they need to synthesize and test in the lab.

Researchers from MIT and the MIT-Watson AI Lab have developed a new, unified framework that can simultaneously predict molecular properties and generate new much more efficiently than these popular deep-learning approaches.

To teach a to predict a molecule’s biological or , researchers must show it millions of labeled molecular structures—a process known as training. Due to the expense of discovering and the challenges of hand-labeling millions of structures, large training datasets are often hard to come by, which limits the effectiveness of machine-learning approaches.

Welcome to this week’s installment of The Intelligence Brief… in recent days, DARPA has announced a new program that aims to protect warfighters from bloodstream infections caused by bacterial and fungal agents. This week, we’ll be examining 1) the announcement of the agency’s new SHIELD program, 2) past challenges that inspired the new DARPA initiative, and 3) how they say SHIELD will manage to clean your bloodstream, similar to a Roomba.

Quote of the Week

“If an alien visited Earth, they would take some note of humans, but probably spend most of their time trying to understand the dominant form of life on our planet – microorganisms like bacteria and viruses.”

Which types of cells can be located in various human tissues, and where? Which genes show activity in these individual cells, and which proteins can be identified within them? Detailed answers to these inquiries and more are expected to be supplied by a specialized atlas. This atlas will particularly elucidate how different tissues take shape during embryonic development and the underlying causes of diseases.

In the process of developing this atlas, the researchers have the goal to chart not just tissues directly procured from humans but also structures referred to as organoids. These are three-dimensional tissue aggregates that are grown in the lab and develop in a manner similar to human organs, albeit on a smaller scale.

“The advantage of organoids is that we can intervene in their development and test active substances on them, which allows us to learn more about healthy tissue as well as diseases,” explains Barbara Treutlein, Professor of Quantitative Developmental Biology at the Department of Biosystems Science and Engineering at ETH Zurich in Basel.

Ever wonder where in your brain that interesting character called “I” lives? Stanford Medicine physician-scientist Josef Parvizi, MD, PhD, has news of its whereabouts.

If skulls were transparent, you still wouldn’t see much going on in someone else’s brain. But Parvizi has ways of peeking into people’s heads and finding out what makes us tick. His experiments have pinpointed specific brain regions crucial to capabilities ranging from perceiving faces to recognizing numerals.

Synthetic cells are a versatile technology with the potential to serve as smart delivery devices or as chassis for creating life from scratch. Despite the development of new tools and improvements in synthetic cell assembly methods, the biological parts used to regulate their activity have limited their reach to highly controlled laboratory environments12. In the field’s preliminary work, well-established arabinose and IPTG-inducible transcription factors and theophylline-responsive riboswitches were used to control in situ gene expression5,6. Still, each performed poorly in vitro and represented a leaky, insensitive route of transcription/translation control. Later, the transition to AHSL-sensitive transcription factors afforded synthetic cells the ability to sense and produce more biologically useful QS molecules, which are central to coordinating collective bacterial behaviors. Although this marked considerable progress toward integrating synthetic cells with living cells, the most frequently adopted QS systems used to date, LuxR/LuxI and EsaR/EsaI, recognize and synthesize the same AHSL (3OC6-HSL), limiting the variety of synthetic cell activators that work orthogonally5,7,10,11.

In this work, we diverged from using naturally derived parts to control gene expression, instead utilizing chemically modified LA-DNA templates to tightly and precisely control the location of synthetic cell activation with UV light. This LA-DNA approach was subsequently implemented to regulate communication with E. coli cells using the BjaI/BjaR QS system, adding this unique branched AHSL into the synthetic cell communication toolbox. We believe this system is ideally suited to synthetic cell communication. It couples an acyl-CoA-dependent synthase, BjaI, which efficiently synthesizes IV-HSL from its commercially available substrates, IV-CoA and SAM, with a highly sensitive IV-HSL-dependent transcription factor, BjaR, that activates gene expression at picomolar concentrations of IV-HSL.

Researchers have combined research with real and robotic insects to better understand how they sense forces in their limbs while walking, providing new insights into the biomechanics and neural dynamics of insects and informing new applications for large legged robots. They presented their findings at the SEB Centenary Conference 2023.

Campaniform sensilla (CS) are force receptors found in the limbs of insects that respond to stress and strain, providing important information for controlling locomotion. Similar force receptors exist in mammals known as golgi tendon organs, suggesting that understanding the role of force sensors in insects may also provide new insights into their functions in vertebrates such as humans.

“I study the role of force sensors in walking insects because these sensors are critical for successful locomotion,” says Dr. Szczecinski, an assistant professor in the Department of Mechanical and Aerospace Engineering in the Statler College of Engineering and Mineral Resources at West Virginia University, U.S. “The feedback they provide is critical for proper posture and coordination.”

Wavebreakmedia/iStock.

The R21/Matrix-M vaccine has been approved for use in children aged five to 36 months, the group at the highest risk of death from the malaria parasite, which is spread by mosquitoes. The vaccine is the first to exceed the World Health Organization’s target of 75 percent efficacy and has demonstrated high levels of safety in Phase II trials.

Year 2019 😗😁


The European Commission approved the world’s first Ebola vaccine. The vaccine is manufactured by Merck and has a trade name of Ervebo.

“The European Commission’s marketing authorization of Ervebo is the result of an unprecedented collaboration for which the entire world should be proud,” said Kenneth C. Frazier, Merck’s chairman and chief executive officer. “It is a historic milestone and a testament to the power of science, innovation and public-private partnership.”

Frazier added, “After recognizing the need and urgency for an Ebola Zaire vaccine, many came together across sectors to answer the global call for outbreak preparedness. We at Merck are honored to play a part in Ebola outbreak response efforts and we remain committed to our partners and the people we serve. We also look forward to continuing to work with the FDA and the African countries on their regulatory reviews over the coming months and with the World Health Organization on vaccine prequalification, which will help broaden access to this important vaccine for those who need it most.”